Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Current Leases (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Current Leases for 5 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 17.01% to $4.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.7 million, a 17.01% increase, with the full-year FY2024 number at $4.1 million, down 24.16% from a year prior.
  • Current Leases was $4.7 million for Q3 2025 at Lyra Therapeutics, up from $4.6 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $5.4 million in Q4 2023 to a low of $654000.0 in Q3 2022.
  • A 5-year average of $2.6 million and a median of $1.7 million in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: plummeted 37.83% in 2022, then surged 250.81% in 2023.
  • Lyra Therapeutics' Current Leases stood at $1.1 million in 2021, then soared by 44.23% to $1.5 million in 2022, then soared by 250.81% to $5.4 million in 2023, then dropped by 24.16% to $4.1 million in 2024, then rose by 13.66% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Current Leases are $4.7 million (Q3 2025), $4.6 million (Q2 2025), and $4.2 million (Q1 2025).